⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6435815 | 0.67 | — | — | |
| SCHEMBL1275536 | 0.67 | — | — | |
| SCHEMBL6438087 | 0.67 | — | — | |
| SCHEMBL4645973 | 0.64 | — | — | |
| SCHEMBL1402540 | 0.64 | — | — | |
| SCHEMBL1022894 | 0.63 | — | — | |
| SCHEMBL12090408 | 0.62 | — | — | |
| SCHEMBL4998480 | 0.61 | — | — | |
| SCHEMBL6431571 | 0.61 | — | — | |
| SCHEMBL6434183 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | claimed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | claimed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | claimed |
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| EP-1120667-B1 | Process for production of optical material | MITSUBISHI GAS CHEMICAL CO (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-20050054618-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | RYTVED KLAUS ASGER (DK) | 2005-03-10 | — | — | US | disclosed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
| US-6472495-B1 | RESIN PRODUCED BY CURING THE COMPOSITION BY POLYMERIZATION HAS AN EXCELLENT IMPACT RESISTANCE AND OPTICAL PROPERTIES, AND IS SUITABLE AS AN OPTICAL MATERIAL. POLYMERS WITH SULFIDE, SELINIUM AND TELLURIUM | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2002-10-29 | — | — | US | disclosed |
| US-6444146-B2 | DISCOLORATION INHIBITION | MITSUBISHI GAS CHEMICAL CO. (JP) | 2002-09-03 | — | — | US | disclosed |
| EP-1120667-A2 | Process for production of optical material | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2001-08-01 | — | — | EP | disclosed |
| US-20010008278-A1 | Process for production of optical material | MITSUBISHI GAS CHEMICAL COMPANY, INC (JP) | 2001-07-19 | — | — | US | disclosed |
| EP-1099721-A1 | Composition for producing resin | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2001-05-16 | — | — | EP | disclosed |
| US-5863903-A | ANTIDIABETIC AGENT | NOVO NORDISK A/S (DK) | 1999-01-26 | — | — | US | disclosed |
| WO-1995024391-A1 | PIPERIDINES AND PYRROLIDINES | NOVO NORDISK A/S (DK) | 1995-09-14 | — | — | WO | disclosed |